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Abstract  1 
Mutations in OCRL encoding the inositol polyphosphate 5-phosphatase OCRL (Lowe 2 
oculocerebrorenal syndrome protein) disrupt phosphoinositide homeostasis along the 3 
endolysosomal pathway causing dysfunction of the cells lining the kidney proximal tubule. 4 
The dysfunction can be isolated (Dent disease 2) or associated with congenital cataracts, 5 
central hypotonia and intellectual disability (Lowe syndrome). The mechanistic understanding 6 
of Dent disease 2/Lowe syndrome remains scarce, due to limitations of animal models of 7 
OCRL deficiency. 8 
Here, we investigate the role of OCRL in Dent disease 2/Lowe syndrome by using OcrlY/- 9 
mice, where the lethal deletion of the paralogue Inpp5b was rescued by human INPP5B 10 
insertion, and primary culture of proximal tubule cells (mPTCs) derived from OcrlY/- kidneys.  11 
The OcrlY/- mice show muscular defects with dysfunctional locomotricity and present massive 12 
urinary losses of low-molecular-weight proteins and albumin, caused by selective impairment 13 
of receptor-mediated endocytosis in proximal tubule cells. The latter was due to accumulation 14 
of phosphatidylinositol 4,5–bisphosphate PI(4,5)P2 in endolysosomes, driving local hyper-15 
polymerization of F-actin and impairing trafficking of the endocytic LRP2 receptor, as 16 
evidenced in OcrlY/- mPTCs. The OCRL deficiency was also associated with a disruption of 17 
the lysosomal dynamic and proteolytic activity. Partial convergence of disease-mechanism 18 
and renal phenotypes observed in OcrlY/- and Clcn5 Y/- mice suggest shared mechanisms in 19 
Dent disease 1 and 2. 20 
These studies substantiate the first mouse model of Lowe syndrome and give insights into the 21 
role of OCRL in cellular trafficking of multiligand receptors. These insights open new 22 
avenues for therapeutic interventions in Lowe syndrome and Dent disease. 23 
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INTRODUCTION 1 
The maintenance of body fluid and electrolyte homeostasis critically depends on the 2 
appropriate handling of solutes and water by the epithelial cells lining the proximal tubule 3 
(PT) of the kidney (1, 2). These cells are characterized by an efficient endolysosomal pathway 4 
involving the apical multiligand receptors megalin (LRP2) and cubilin (3). By processing 5 
internalized cargos and recycling of receptors and transporters at the apical surface, the 6 
endolysosomal system of the PT cells recover essential substances that are filtered through the 7 
glomerulus, including a large variety of low-molecular-weight (LMW) proteins that would 8 
otherwise be lost in the urine (2). Congenital and acquired disorders of the endolysosomal 9 
pathway cause PT dysfunction (renal Fanconi syndrome) with massive urinary loss of solutes, 10 
dehydration, electrolyte imbalance, rickets, growth retardation, and the development of 11 
chronic kidney disease (CKD). Such PT dysfunctions are typically encountered in Dent 12 
disease, a rare, X-linked disorder characterized by LMW proteinuria, renal Fanconi syndrome, 13 
kidney stones, nephrocalcinosis and progressive renal failure (4, 5). 14 
 Dent disease is genetically heterogeneous. The majority of cases (approx. 60%) is due 15 
to mutations in the CLCN5 gene that encodes the electrogenic Cl-/H+ exchanger ClC-5 (Dent 16 
disease 1, MIM # 300009) (6). In a subset of patients (~15-20%), the disease is caused by 17 
mutations in OCRL, the gene encoding the type II phosphatidylinositol (PI) bisphosphate 5-18 
phosphatase OCRL (Dent disease 2, MIM #300555). Mutations in OCRL are also associated 19 
with the oculocerebrorenal syndrome of Lowe (MIM # 309000), which includes systemic 20 
manifestations such as congenital cataracts, cognitive disability and hypotonia (4, 7). OCRL 21 
is a protein of 110 kDa which, in addition to the 5-phosphatase catalytic domain, comprises: 22 
(i) a pleckstrin homology (PH) domain containing a clathrin-binding site (8); (ii) an ASPM, 23 
SPD-2, Hydin (ASH) domain, characteristic of protein that localizes to centrosome and 24 
primary cilia (9); and (iii) a RhoGAP-like domain, which mediates interactions involved in 25 
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cytoskeleton dynamics and progression of cell cycle (10). Almost all the mutations associated 1 
with Lowe syndrome occur in exons 8-23 which include the 5-phosphatase catalytic domain, 2 
the ASH domain and the RhoGAP-like domain. Conversely, the majority of mutations that 3 
cause Dent disease 2 are positioned in exons 1-7 which comprise the PH domain (11). 4 
Although mutations in the catalytic domain of OCRL have been described in both clinical 5 
profiles, the mutations in Dent disease 2 are always missense - compatible with a residual 6 
biological activity that could explain a less severe cellular phenotype (7). 7 
 The convergence of clinical phenotypes among patients with mutations in OCRL and 8 
CLCN5 raises the questions whether these genes products are part of the same pathways and 9 
how they cause dysfunction of endolysosomes in PT cells. ClC-5 is predominantly expressed 10 
in the early endosomes of PT cells of the kidney, potentially involved in their maturation 11 
towards the degradative compartments or the recycling route (6). Studies in mouse models 12 
showed that the functional loss of ClC-5 generates a trafficking defect involving megalin and 13 
cubilin, reflected by defective endocytosis and manifestations of PT dysfunction (6, 12). 14 
OCRL is located at different stations of the endo-lysosomal pathway where it maintains the 15 
cellular metabolism of phosphatidylinositol 4, 5-bisphosphate PI(4,5)P2 , an essential 16 
regulator of membrane trafficking. Increased PI(4,5)P2 levels and marked vesicular trafficking 17 
defects affecting the endocytic network have been observed in cells lacking OCRL, resulting 18 
in defective receptor-mediated endocytosis (13).  19 
 The direct impact of OCRL on transport events leading to renal Fanconi syndrome 20 
cannot be reliably assessed on dedifferentiated cell systems including non-kidney or non-21 
epithelial cell types, or clonal cells isolated from urine (14). Renal biopsy material, usually 22 
obtained at an advanced disease stage, is of limited value. Furthermore, limitations of animal 23 
models of OCRL deficiency impede the development of translational studies. The first Ocrl 24 
KO mouse showed no kidney, eye or brain defects (15), due to a compensation by INPP5B, 25 
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the closest paralogue of OCRL in mice and humans (16). Accordingly, a generalized 1 
endocytic defect (affecting both receptor-mediated and fluid-phase endocytosis) was detected 2 
in a conditional tubular deletion of Ocrl and Inpp5b mouse model (17). However, studies 3 
performed in this strain do not allow to discriminate the individual role of OCRL and INPP5B 4 
in the pathophysiology of Dent disease. 5 
  Recently a mouse model expressing human INPP5B in OcrlY/-; Inpp5b−/− background 6 
was generated (18). The replacement of mouse Inpp5b with human INPP5B in the whole 7 
body of OcrlY/- mouse provides a humanized background, which therefore allows to 8 
investigate the consequences related to the specific loss of OCRL activity. Preliminary studies 9 
revealed PT dysfunction in this line (18), with no investigation of the time-course, multi-10 
systemic aspect, and cellular basis of this defect. Here, we analyzed in detail the multi-11 
systemic phenotype of these OcrlY/-; Inpp5b-/-; BAC-INPP5B mouse model; compared the 12 
kidney dysfunction to that of Clcn5 KO mice; and investigated the mechanisms underpinning 13 
epithelial transport defects in Lowe syndrome.   14 
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RESULTS 1 
OcrlY/- mice show early manifestations of proximal tubule dysfunction 2 
A humanized mouse model for Lowe syndrome/Dent disease 2 was generated by targeted 3 
disruption of both Ocrl and Inpp5b and oocyte injection of a bacterial artificial chromosome 4 
(BAC) containing the human gene INPP5B to avoid embryonic lethality (18). The mouse 5 
littermates lacking Inpp5b while harbouring BAC-INPP5B expression with Ocrl are referred 6 
to as OcrlY/+ (OcrlY/+; Inpp5b-/-; BAC-INPP5B) whereas those lacking Ocrl are OcrlY/ - (OcrlY/-; 7 
Inpp5b-/-; BAC-INPP5B) mice, respectively. All mice were born at mendelian ratio and were 8 
viable and fertile. The genotype of Ocrl mice was demonstrated by genomic DNA analyses of 9 
Ocrl, Inpp5b and BAC-INPP5B (Suppl. Fig. 1A) and immunoblotting for OCRL (Suppl. Fig. 10 
1B) in kidney samples derived from OcrlY/- and OcrlY/+ mice.  11 
We first used the Ocrl mice to characterize the kidney phenotype over time. Growth 12 
retardation was observed in OcrlY/- mice starting from 16 weeks of age onwards (Fig. 1A), 13 
whereas manifestations of PT dysfunction appeared in OcrlY/- mice from 8 weeks of age, with 14 
albuminuria (Figs. 1B and 1C) and LMW proteinuria (Figs. 1D and 1E). The inappropriate 15 
loss of the LMW clara cell secretory protein 16 (CC16) in the urine of OcrlY/- mice was 16 
observed at all time points analyzed (Fig. 1D). Western blotting of the urine confirmed the 17 
major loss of transferrin (TFR) and vitamin D binding protein (VDBP) along CC16 in the 18 
urine of OcrlY/- mice (Fig. 1E). The OcrlY/- mice did not show manifestations of renal failure, 19 
and no polyuria, calciuria, glycosuria and phosphaturia during the timeframe of investigation, 20 
suggesting a partial renal Fanconi syndrome (Table 1). The expression levels of BAC-INPP5B 21 
were not associated with variable levels of PT dysfunction in OcrlY/- mice (Suppl. Figs. 1C-F). 22 
Since mutations in CLCN5 and OCRL produce similar kidney defects in human patients, we 23 
compared the severity of PT dysfunction in the Clcn5Y/- and OcrlY/- mouse models. The OcrlY/- 24 
mice display a milder LMW proteinuria (CC16) than that observed in Clcn5Y/- mice (Fig. 1F). 25 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy449/5261432 by U
niversity of Zurich user on 07 January 2019
7 
 
This difference is most likely reflecting specific roles of ClC-5 and OCRL along the endo-1 
lysosomal pathway.  2 
 3 
OcrlY/- mice show a specific defect in receptor-mediated endocytosis 4 
To determine the mechanism of LMW proteinuria, we followed the in vivo uptake of the 5 
LMW protein Cy5-labelled β-lactoglobulin in the kidneys of OcrlY- mice compared to their 6 
control littermates. Fifteen minutes after injection, a substantial accumulation of 7 
fluorescent vesicles was observed in the brush border of PT cells of the OcrlY/+ mice, 8 
contrasting with a considerable reduction of the signal in PT cells from OcrlY/- mice (Fig. 9 
2A). A similar defective uptake in Cy5-labelled β-lactoglobulin was observed in Clcn5Y/- 10 
tubules (Fig. 2B). By contrast, the internalization of Alexa 647-dextran, a marker of fluid 11 
phase endocytosis, was unaltered in OcrlY/- mice (Fig. 2C), suggesting that loss of OCRL 12 
function impacts specifically on receptor-mediated endocytosis. To substantiate this 13 
observation, we investigated the LRP2 receptor and found its expression dramatically 14 
decreased in PT cells of the OcrlY/- kidneys whereas its mRNA level was unchanged (Figs. 15 
2D-F). In line with absent phosphaturia and glycosuria, no modifications in the sodium- 16 
phosphate cotransporter IIa (NaPi-IIa), the sodium-glucose cotransporter 2 (SGLT2) or other 17 
PT components were observed in OcrlY/- kidneys (Figs. 2E and 2F).  18 
These data reveal that a defective receptor-mediated endocytosis, caused by a decreased 19 
protein level of LRP2, characterizes OcrlY/- mice, similar to Clcn5Y/- mice. The renal 20 
Fanconi syndrome is restricted to LMW proteinuria in OcrlY/- mice, contrasting with a 21 
more severe PT dysfunction in Clcn5Y/- mice. At age 8 weeks, the latter showed a 22 
decreased expression of SGLT2 and NaPi-IIa (Suppl. Fig. 2A), explaining glycosuria and 23 
phosphaturia along polyuria and calciuria (Table 1; Suppl. Figs. 2C-D), and a defective 24 
uptake of fluid-phase endocytosis (dextran) markers (Suppl. Fig. 2B).  25 
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Loss of OCRL increases PI(4,5)P2 and disrupts receptor-mediated endocytosis in vitro 1 
In order to further analyse the endocytic defect observed in vivo, we developed primary 2 
cultures of PT cells (mPTC) from micro-dissected PT segments of OcrlY/- mice aged 8 weeks. 3 
This cell culture system preserves the differentiation and polarized transport processes and 4 
therefore represents a relevant in vitro model to investigate mechanisms underlying PT 5 
disorders (19). To validate the Ocrl cellular system, we evaluated whether the loss of OCRL 6 
in mPTC reproduced the typical endosomal accumulation of PI(4,5)P2 observed in Lowe 7 
syndrome/Dent disease2 (20). Compared to control, OcrlY/- mPTCs exhibited a remarkable 8 
increase of PI(4,5)P2  in early endosomal structures, as shown by colocalization with the early 9 
endosome marker EEA1 (Figs. 3A-B). The unchanged PI3P levels, the PI hallmark of the 10 
endosomal system, demonstrated that OCRL disruption in mPTCs exclusively targets the 11 
homeostasis of PI(4,5)P2 (Suppl. Fig. 3A). These results, which are consistent with PI(4,5)P2 12 
accumulation observed in a transgenic zebrafish model of Lowe syndrome or in OCRL-13 
depleted immortalized cells, substantiate the reliability of Ocrl mPTCs system (13, 21). 14 
Given that the tight regulation of PI(4,5)P2 homeostasis is fundamental for a proper endocytic 15 
trafficking, we asked whether its increase at the early endosomes might impair the endocytic 16 
function of mPTCs. Functional studies demonstrated that albumin uptake was markedly 17 
reduced in OcrlY/- (-84%) when compared to control mPTCs (Fig. 3C). A similar disruption of 18 
the endocytic capacity was observed in Clc5Y/- mPTCs (Fig. 3D). Confirming the observations 19 
made in vivo, fluid phase endocytosis was unaltered in OcrlY/- mPTCs (Fig. 3E), highlighting 20 
the specificity of the defect in receptor-mediated endocytosis.  21 
 22 
OCRL deficiency perturbs expression of LRP2 through aberrant F-actin polymerization  23 
We next examined whether the defective uptake capacity of OcrlY/- mPTCs was reflected by 24 
alterations of the endogenous LRP2 expression. LRP2 protein level was reduced in the total 25 
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lysates of mPTCs lacking OCRL (Fig. 4A), similarly to Clcn5Y/- mPTCs (Suppl. Fig. 4A). 1 
This reduction was confirmed by the analysis of the confocal Z-stack images, evidencing a 2 
decreased LRP2 fluorescent signal in each focal plane throughout the entire volume of OcrlY/- 3 
mPTCs (Fig. 4B and Suppl. Fig. 4B). The latter analysis showed a shift of LRP2 signal from 4 
the apical plasma membrane towards a more intracellular compartment in OcrlY/- mPTCs, 5 
whose polarization is defined by the typical apical (wheat germ agglutinin, WGA) and 6 
basolateral (Na+, K+-ATPase) markers (Fig. 4C and Suppl. Fig. 4C). This result was 7 
corroborated by a striking decrease of LRP2 level in the plasma membrane fraction of OcrlY/- 8 
mPTCs (Fig. 4D). These changes were not associated with LRP2 transcriptional 9 
modifications or alterations of other PT receptors or transporters (Suppl. Fig. 3B).  10 
The intracellular localization of LRP2 in OcrlY/- mPTCs prompted us to examine its 11 
organelles compartmentalization. OCRL is known to modulate the trafficking of endocytic 12 
receptors by orchestrating the recycling of endosomal vesicles to the surface (13). Thus, lack 13 
of OCRL function might disrupt the return of the endocytic receptors to the apical membrane, 14 
leading to their accumulation in endosomal structures. Imaging studies confirmed LRP2 15 
increase within EEA1+ early endosomes in OcrlY/- mPTCs, suggesting that loss of OCRL 16 
function impacts on both expression and distribution of this endocytic scavenger (Fig. 4E).  17 
As PI(4,5)P2 promote the recruitment of the actin nucleating machinery, we asked whether 18 
their endosomal accumulation, observed in OcrlY/- mPTCs, might locally induce an aberrant 19 
actin polymerization and, in turn, affect the trafficking of endocytic receptors (22).We 20 
observed that, in OcrlY/- mPTCs, the levels of actin stress fibres decreased and foci of 21 
filamentous actin (F-actin) accumulated on internal membranes ruffles (Suppl. Fig. 4D).   22 
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Compared to controls, an increase of F-actin structures, colocalizing with EEA1, was 1 
observed in OcrlY/- mPTCs (Suppl. Fig. 4E). This uncontrolled actin dynamics might impede 2 
the entrance of the endosomes in the recycling route and coerce LRP2 to stick inside them. 3 
Supporting this hypothesis, a considerable amount of LRP2 vesicles were coalescent with F-4 
actin membranes (Fig. 4F). Furthermore, by high magnification confocal microscopy, it was 5 
possible to visualize the formation of F-actin basket-like structure surrounding LRP2 (Suppl. 6 
Fig. 4F). These data indicate that the increased association of F-actin with early endosomes 7 
may affect the endocytic trafficking and prevent the recycling of LRP2 to the apical surface. 8 
In order to substantiate the role of OCRL in maintaining the recycling activity, we 9 
investigated the localization of the canonical recycling marker transferrin receptor (TfR), 10 
which crosses the same endocytic stations traveled by LRP2 (plasma membrane - early 11 
endosomes/recycling endosomes) (23). Our data showing the redistribution of TfR from the 12 
plasma membrane to enlarged cytoplasmic structures, which also trap LRP2, provide another 13 
evidence of defective endocytic recycling in OcrlY/- mPTCs (Suppl. Fig. 5A and Fig. 4G).  14 
We also tested whether the lack of OCRL might affect the trafficking of the cation-15 
independent mannose 6-phosphate receptor (CI-MPR), which is required for the transport of 16 
lysosomal enzymes and travels through intracellular itineraries diverging from those exploited 17 
by LRP2 (trans golgi network-late endosomes- plasma membrane) (24). An increase in the 18 
CI-MPR associated with peripheral structures and a decrease in the perinuclear pool was 19 
observed in the kidneys and mPTCs from OcrlY/– mice compared to controls (Suppl. Figs. 5B-20 
C), indicating a defective retrograde transport of CI-MPR from the endosomes to the Golgi. 21 
All together, these data suggest that the actin-trapping mechanism impairing the recycling of 22 
LRP2 extends to other receptors traveling through the endosomal structures of OcrlY/- mice, 23 
highly relevant for the molecular basis of Lowe syndrome.  24 
 25 
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OCRL depletion alters lysosomal dynamics and function 1 
It has been recently shown that, under lysosomal overload conditions, OCRL translocates on 2 
the lysosomal membrane, where it ensures adequate levels of PI(4,5)P2 necessary for fusion 3 
and subsequent degradation of  cargo vesicles (25). We thus explored whether loss of OCRL 4 
function might generate a rearrangement of PI(4,5)P2 at the lysosomal membrane and, 5 
consequently, affect lysosomal morphology. Confocal microscopy analysis showed that Ocrl 6 
deletion increased the number of PI(4,5)P2 positive structures colocalized with LAMP1-7 
labeled lysosomes (Fig. 5A). These changes were associated with dramatic modifications in 8 
the dynamics of lysosomes as evidenced by their abnormal increase in number and size (Fig. 9 
5B). As changes in lysosomal dynamics could affect their proteolytic activity, we examined 10 
whether OCRL disruption impairs the lysosomal cargo degradation in OcrlY/- mPTCs. To this 11 
end we used dequenched BSA (BSA-DQ) reagent, which is readily incorporated by cells via 12 
fluid-phase endocytosis. Upon fusion with endo-lysosomes, BSA-DQ is digested into smaller 13 
fragments, thereby relieving its self-quenching properties and causing a fluorescent signal that 14 
reflects lysosomal degradative capacity (26). OcrlY/- mPTCs showed a remarkable decrease in 15 
BSA-DQ fluorescent puncta colocalized with LAMP1 (Fig. 5C), indicating a specific 16 
impairment of lysosomal proteolysis as fluid phase endocytosis was not affected by the loss of 17 
OCRL. To substantiate the defective lysosomal activity, we tested the processing of the 18 
epidermal growth factor receptor (EGFR), an endogenous protein which, upon EGF induced 19 
internalisation, is normally sorted to endo-lysosomal proteolytic pathway for degradation 20 
(27). Control mPTCs, 90 min after EGF stimulation, showed an efficient degradation of 21 
EGFR. On the contrary, at the same time frame, the levels of EGFR remained high in OcrlY/- 22 
mPTCs, suggesting a delayed lysosomal processing of the receptor (Fig. 5D).   23 
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One mechanism by which cargo clearance might be impeded is a defective maturation of 1 
lysosomal cathepsins. Western blot analyses of Cathepsin D (Cts-D) showed a decreased 2 
generation of the 32kDa mature Cts-D in OcrlY/- mPTCs compared to control (Fig. 5E). We 3 
next tested the lysosomal Cts-D activity by incubating the cell with Bodipy-FL-PepstatinA 4 
(PepA), a fluorescence-tagged PepA that binds to the active site of Cts-D in acidic lysosomes. 5 
Although the majority of lysosomes were co-stained with PepA in control mPTCs, the 6 
number of PepA-labeled vesicles colocalizing with LAMP1 were substantially lower in 7 
OcrlY/- mPTCs (Fig. 5F). Similarly, the lysosome-based processing of the LMW -8 
lactoglobulin, which is normally internalized and degraded by endolysosomes, was 9 
dramatically reduced in OcrlY/- proximal tubules compared to wild-type (Fig. 5G).  10 
To investigate whether mis-sorting of lysosomal hydrolases in the extracellular space might 11 
contribute to the aberrant lysosomal proteolysis observed in OcrlY /– mice, we tested for and 12 
detected significantly increased levels of the lysosomal protease Cts-D (immature form) in the 13 
plasma of these mice (Suppl. Fig. 6A). This result was in line with the mis-trafficking of CI-14 
MPR at the cell periphery and with previous studies performed in patients with Lowe 15 
syndrome (13). Collectively these data indicate that OCRL is important to maintain lysosome 16 
homeostasis, itself crucial for PT function. Of note, impaired lysosomal proteolysis and 17 
insufficient degradation of β-lactoglobulin was also observed in Clcn5Y/- proximal tubules 18 
(Suppl. Figs. 6B-D) indicating that OCRL and ClC-5 are part of the same cellular pathways. 19 
 20 
The OcrlY/- mice show dysfunctional locomotricity associated with muscular defects 21 
In order to test whether the deletion of OCRL in this model was reflected by extra-renal 22 
manifestations, we performed comprehensive behavioral tests of Ocrl mice to examine basic 23 
motor activity, learning and memory skills, social behaviour and vision.   24 
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To identify disturbances in locomotor activity, we evaluated the general mobility of the mice 1 
by challenging them with the open field large arena test, which has been extensively used for 2 
analyzing the locomotor defects exhibited by Parkinson and Huntington mouse models (28, 3 
29). While velocity was comparable between genotypes (data not shown), OcrlY/- mice 4 
exhibited an overall decreased locomotor activity, as scored by the measurement of their 5 
trajectories (Figs. 6A and 6B). The OcrlY/- mice presented more resting episodes than controls, 6 
as well as fewer lingering and walking events during the test (Fig. 6C). Of note, center-field 7 
avoidance was robust and equal in both genotypes (data not shown), suggesting that the 8 
impaired motor activity in OcrlY/- mice was more likely driven by a muscular defect rather 9 
than an abnormal anxiety-related response.  10 
To test the latter hypothesis, we pursued mice analyses in IntelliCage, an automated system, 11 
which allowed the evaluation of the spontaneous behaviour of the animals (30). During free 12 
adaptation phase, OcrlY/- mice made fewer corner visits compared to controls, confirming the 13 
reduced locomotor and exploratory activity shown in the test above (data not shown). 14 
However, OcrlY/- mice showed an incompetent licking pattern, which became more evident 15 
during the drinking restriction protocol and was associated with slower progress of water 16 
intake during drinking sessions (Fig. 6D).We excluded an influence of the kidney defect on 17 
the licking pattern as similar water intake was detected between genotypes (Suppl. Fig. 7A). 18 
Thus, the impaired licking of OcrlY/- mice was most likely caused by a global muscular 19 
dysfunction, which affected also the oro-lingual motor apparatus.  20 
To explore whether the defective locomotricity evidenced in OcrlY/- mice was driven by 21 
muscular defects, we used whole body composition analysis (EchoMRI) to evidence a 22 
striking decrease in lean mass/body weight ratio in OcrlY/- mice compared to controls (Fig. 23 
6E), with a global reduction of the mass of several hind limb (gastrocnemius, triceps surae, 24 
plantaris, tibialis posterior/anterior and quadriceps) muscles relative to body weight (Fig. 6F) 25 
demonstrating skeletal muscle atrophy. These changes were paralleled by a strong increase in 26 
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plasma creatine kinase (CK) activity, suggesting membrane fragility of striated muscles. (Fig. 1 
6G). These events, which are in line with the muscle hypotonia observed in Lowe Syndrome 2 
patients (7), support the motor defect detected in OcrlY/- mice. 3 
To assess the cognitive function of Ocrl mice we applied IntelliCage standard protocol which 4 
investigated the hippocampus-dependent spatial learning ability of the animals. No sign of 5 
dysfunctional learning was observed in OCRL deficient mice, even during the most 6 
challenging chaining task (data not shown). Aggressive behavior reported in patients with 7 
Lowe syndrome was also not reflected in OcrlY/- mice, which showed intact sociability (Suppl. 8 
Fig. 7B). Given that congenital cataract and glaucoma are hallmarks of Lowe syndrome, we 9 
also examined the visuospatial and visuoperceptual ability of Ocrl mice. During water maze 10 
cue navigation, OcrlY/- mice exhibited a robust learning without evidences for an inadequate 11 
vision (Suppl. Fig. 7C). In addition no noticeable differences were observed in lens 12 
epithelium and in retinal morphology between control and OcrlY/- mice. Irrespective of the 13 
Ocrl genotype, an impairment of retinal photoreceptor layer was observed in mice harboring 14 
rd8 (retinal degeneration 8) mutation in Crb1 gene, a spontaneous mutation associated with 15 
C57BL/6N genetic background, leading to photoreceptor rosette-like structures when 16 
expressed homozygously (rd8/rd8). (Suppl. Figs.7D and 7E) (31). 17 
 18 
19 
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DISCUSSION  1 
In these studies we present the first OCRL-deficient mouse model that associates renal and 2 
extra-renal manifestations encountered in patients with Lowe syndrome. The absence of 3 
OCRL in kidney proximal tubule triggers endolysosomal defects and epithelial dysfunction, 4 
with a consistent LMW proteinuria reflecting defective receptor-mediated endocytosis due to 5 
decreased expression of LRP2 endocytic receptor, in absence of renal failure. We also 6 
evidence a partial convergence of disease-mechanism and kidney tubular phenotype between 7 
mouse models deficient in ClC-5 (Dent disease 1) and OCRL (Lowe syndrome/Dent disease 8 
2). These results provide insights into the mechanisms of endocytosis and the 9 
pathophysiology of Dent disease/Lowe syndrome. 10 
 In contrast with a previous kidney tubular conditional Ocrl and Inpp5b KO mouse 11 
model, where the phenotype reflects the combined loss of OCRL and INPP5B (17), the 12 
genetic architecture of the mouse line investigated here allows to directly address 13 
dysfunctions related to the single loss of OCRL activity (18). The reinsertion of human 14 
INPP5B in the Ocrl−/−; Inpp5b−/− background, irrespective of its level of expression, was 15 
fundamental for survival but it was not compensating for the renal defect. This observation is 16 
in line with studies on cells derived from patients with Lowe syndrome, which exhibit 17 
INPP5B-independent phenotypic variability (32). Although the renal defect was observed in 18 
all the OcrlY/- mice analysed, a noticeable spread was observed comparing individual animals. 19 
This individual variability was not due to different levels of INPP5B expression. The 20 
possibility that compensatory changes in kinases or phosphatases crossing the same metabolic 21 
pathway than OCRL may contribute to such variability should be further investigated. 22 
The differences between the conditional double Ocrl and Inpp5b KO and the 23 
humanized transgenic OcrlY/- mice studied here are evident when comparing the defective 24 
tubular endocytic phenotypes. The conditional deletion of OCRL and INPP5B resulted in an 25 
unspecific impairment of the clathrin-dependent and clathrin-independent endocytosis. By 26 
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contrast, the single lack of OCRL in OcrlY/- transgenic mice resulted in a selective dysfunction 1 
of the clathrin receptor-mediated endocytosis, as evidenced by the defective uptake of β-2 
lactoglobulin and the unaffected internalization of the fluid-phase marker dextran. These 3 
differences are in line with the function of OCRL in regulating the membrane trafficking of 4 
clathrin coated vesicles (33). 5 
Defective receptor-mediated endocytosis was reflected in OcrlY/- mice by a consistent 6 
LMW proteinuria, occurring early, in absence of renal failure. In contrast, the OcrlY/- mice did 7 
not show glycosuria, phosphaturia and calciuria, even at old age, mimicking the partial renal 8 
Fanconi syndrome typically present in the majority of patients carrying mutations in OCRL 9 
(7, 34). The Clcn5Y/- mice showed a similar defect in receptor-mediated endocytosis, causing 10 
a severe LMW proteinuria. The Clcn5Y/- mice also showed a defective uptake of fluid phase 11 
endocytosis markers, in line with previous data from mouse models and patient-derived cells 12 
(35-37) but not with others (12). The presence of a more complete form of renal Fanconi 13 
syndrome in the Clcn5Y/- mouse model was evidenced by the hypercalciuria, phosphaturia and 14 
glucosuria detected at 8 weeks, paralleled by a decreased expression of SGLT2 and NaPi-IIa 15 
in addition to LRP2.  16 
Filtered LMW proteins are reabsorbed through megalin /LRP2 and cubilin endocytic 17 
receptors expressed at the apical membrane of PT cells. This reabsorptive function is 18 
maintained by the degradative and recycling activity of the endolysosomal system, as 19 
evidenced by severe defects in tubular homeostasis associated with endolysosomal disorders 20 
(1, 2). Our investigations characterize the involvement of LRP2 in the pathogenesis of Lowe 21 
syndrome, and demonstrate analogies with the endocytic defect associated with the loss of 22 
ClC-5 in Dent disease1/Clcn5Y/- mouse model (12). Previous studies, relying on OCRL-23 
deficient immortalized cells expressing LRP2 mini‐receptor, showed a redistribution of LRP2 24 
from the apical membrane to the intracellular compartments rather than a defective expression 25 
(13). Here, analyses on kidney tissues reveal a remarkable decrease of LRP2 protein in the 26 
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proximal tubule from OcrlY/- mice, similar to that observed in Clcn5Y/- mice. These findings 1 
are in line with observations made in zebrafish pronephros, demonstrating the evolutionary 2 
conservation of the role of OCRL in endocytosis (21). The identification of converging 3 
kidney phenotypes in mouse models for Lowe syndrome and Dent disease supports the view 4 
that the endosomal exchanger ClC-5 and the 5-phosphatase OCRL impact on common 5 
pathways operating in kidney tubular cells. In absence of transcriptional changes, the 6 
mechanism by which the loss of ClC-5 or OCRL might affect LRP2 protein levels remains to 7 
be clarified. First, the decrease of apical LRP2 may reflect an increased shedding of the 8 
receptor in the urine in response to the endolysosomal engorgement observed in OcrlY/- mice. 9 
Previous studies showed that LRP2 is a substrate for metalloproteases and is constitutively 10 
subjected to ectodomain shedding (38). This event produces LRP2 membrane-associated 11 
fragments, which in turn form the substrate for - secretase, the main player of regulated 12 
intramembrane proteolysis. Preliminary data showing a higher abundance of LRP2 fragments 13 
in OcrlY/- urine, together with a transcriptional increase of all subunits composing the -14 
secretase (39) are in line with this hypothesis (data not shown). Alternatively, the loss of 15 
LRP2 could be explained by an increased urinary excretion of (full length) LRP2-containing 16 
exosomes. A third mechanism might be an aberrant degradation of LRP2, mediated by the 17 
proteasome in response to altered lysosomal proteolysis (see below). Further studies of post-18 
translational modifications potentially triggering LRP2 to the proteasome are necessary to test 19 
this hypothesis (40). 20 
By establishing differentiated and polarized proximal tubular cell cultures (mPTCs) 21 
directly derived from OcrlY/- mouse kidneys (19), we were able to reconstitute critical aspects 22 
of the disease in vitro. The OcrlY/- mPTCs recapitulate the selective impairment of receptor-23 
mediated endocytosis and the ectopic accumulation of PI(4,5)P2 in early endosomes (20). The 24 
latter is due to the loss of 5-phospatase activity of OCRL that regulates the transition from 25 
high (plasma membrane) to low (early endosomes) levels of PI(4,5)P2  in clathrin coated 26 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy449/5261432 by U
niversity of Zurich user on 07 January 2019
18 
 
vesicles, enabling progression of the cargo/receptor along the endocytic pathway (33, 41). 1 
The PI(4,5)P2 dynamic is critical for actin assembly at the plasma membrane ruffles and early 2 
endosomes, hence, for the regulation of membrane trafficking (42, 43). Accordingly, the 3 
endosomal accumulation of PI(4,5)P2  in Ocrl
Y/- mPTCs triggers an aberrant F-actin 4 
polymerization, which impairs the recycling of residual LRP2, thus impeding the endocytic 5 
uptake. The actin-trapping mechanism impairing LRP2 recycling might be extended to other 6 
receptors, as evidenced by the redistribution of the canonical recycling marker TfR in OcrlY/- 7 
mPTCs. These defects in receptor recycling represent an appealing druggable target for 8 
rescuing the epithelial dysfunction associated with the disease. 9 
It has been shown recently that OCRL can translocate to the lysosome under cargo 10 
overload conditions, where its fine regulation of PI(4,5)P2 balance is instrumental for 11 
maintaining lysosomal function (25). Here, we demonstrate that lack of OCRL induces an 12 
abnormal lysosomal accumulation of PI(4,5)P2 leading to altered lysosomal dynamics and 13 
defective lysosomal function, as scored by decreased expression and activity of lysosomal 14 
cathepsin D and impaired processing of lysosomal substrates in OcrlY/- kidney and mPTCs. 15 
These results, which are consistent with previous observations on biopsies derived from Lowe 16 
patients (25), raise the issue of the mechanisms responsible for lysosomal dysfunction 17 
associated with loss of OCRL. The peripheral mislocalization of the CI-MPR, a protein 18 
regulating the transport of lysosomal hydrolases from the Golgi to lysosomes, along with 19 
increased levels of lysosomal protease Cathepsin D (immature form) in the plasma, indicates 20 
that misrouting of lysosomal enzymes could be involved. This finding is in line with previous 21 
studies performed in Lowe syndrome patients (13). Alternatively, the lysosomal engulfment 22 
of PI(4,5)P2 driven by the loss of OCRL may somehow alter the vacuolar-type H+-ATPase 23 
(V-ATPase) complex, thereby impairing lysosome acidification and activation of cathepsins. 24 
It should be noted that similar defects in receptor-mediated endocytosis and lysosomal 25 
dynamic and activity are observed in mouse and cellular models deficient for the endosomal 26 
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ClC-5 or lysosomal cystinosin (CTNS) transporters, highlighting the role of the endolysosome 1 
network as crucial signaling hub to ensure epithelial homeostasis (44). 2 
Studies on the locomotor, neurological and vision abnormalities detected in patients 3 
with Lowe syndrome have been hindered by the limitations of available mouse models. Deep 4 
phenotyping analyses unveiled a defective locomotricity in OcrlY/-mice, which reflects a 5 
global impairment of the muscular apparatus, as indicated by the increased plasma activity of 6 
protein creatine kinase and atrophy of several hind limb muscles. This phenotype was 7 
reminiscent of the muscle hypotonia associated with Lowe syndrome and therefore highly 8 
relevant (45). Whether this defective muscular/motor pattern originates from a primary 9 
myopathy or is rather a consequence of neurological alterations and how OCRL contributes in 10 
maintaining muscular tone remains to be further investigated. Behavior, learning-memory 11 
function and vision were not altered in OcrlY/-mice. The discrepant clinical manifestations in 12 
mice and humans could be partly explained by differences in tissue-specific expression of 13 
enzymes with overlapping functions or by specific roles of OCRL in the tissues affected by 14 
the disease (46, 47).  15 
Collectively, these studies validate the first mouse model of Lowe syndrome and give 16 
insights into the role of OCRL in cellular trafficking of multiligand receptors. Partial 17 
convergence of disease-mechanism and renal phenotypes observed in OcrlY/- and Clcn5 Y/- 18 
mice suggest shared mechanisms in Dent disease 1 and 2. These insights open new avenues 19 
for therapeutic interventions in Lowe syndrome and Dent disease. 20 
  21 
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MATERIALS AND METHODS  1 
Antibodies and reagents. The following antibodies were used: rabbit anti-human transferrin 2 
(A0061, Dako); rabbit anti-human Gc-globulin (also known as VDBP, A0021, Dako); rabbit 3 
anti-uteroglobin (also known as CC16, ab40873, Abcam); rabbit anti-SLC1A5 (also known as 4 
SGLT2, ab84903, Abcam); rabbit NaPi-IIa (gift from C.A.Wagner, University of Zurich, 5 
Zurich, Switzerland); rabbit anti-human AQP1 (ab2219, Millipore); mouse anti--actin 6 
(A2228, Sigma-Aldrich); mouse conjugated to Fluorescein (FITC) anti-PI(4,5)P2 (Z-G045, 7 
Echelon Biosciences Inc.); mouse anti-EEA1 (610456, BD Bioscience); rabbit anti-RFP (600-8 
401-379, ROCKLAND); sheep anti-LRP2 (gift from P. Verroust and R. Kozyraki, INSERM, 9 
Paris, France); mouse anti Flotillin-1(610821, BD Bioscience); mouse anti-α-tubulin (T5168, 10 
Sigma-Aldrich); rabbit anti-GAPDH (2118, Cell Signaling Technology); rat anti-LAMP1 11 
(sc-19992, Santa Cruz Biotechnology);  goat anti-Cathepsin-D (Cts-D; sc-6486, Santa 12 
Cruz Biotechnology); rabbit anti-EGFR (1005 sc-03, Santa Cruz Biotechnology); 13 
Alexa-488 Phalloidin (F-actin , A12379, Thermofisher Scientific); mouse anti-Transferrin 14 
Receptor Antibody (H68,4, ThermoFisher Scientific), wheat germ agglutinin 15 
(WGA) FITC Conjugate (L 4895, Sigma-Aldrich), mouse anti-Na+/K+-ATPase 16 
subunit 1 (C464.6 EMD Millipore), rabbit anti-MPR and rabbit anti-OCRL (gift 17 
from A. De Matteis, Telethon Institute of Genetics and Med icine (TIGEM), 18 
Pozzuoli, Italy). 19 
 20 
Mouse models. Experiments were conducted on age- and gender-matched OcrlY/+; Inpp5b-/-; 21 
and OcrlY/-; Inpp5b-/- mouse littermates harboring BAC-INPP5B expression in equal copies 22 
(BAC1) (129S/SvEv * 129S6/SvEvTac * FVB/N* C57BL/6 background), (18) and 23 
Clcn5Y/+and Clcn5Y/- mice littermates (C57BL/6 background) (48). All the mice used in this 24 
study were expressing similar levels of INPP5B as analyzed by RT-qPCR (see below). Mice 25 
were maintained under temperature-and humidity-controlled conditions with 12 h light/12 h 26 
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dark cycles with free access to appropriate standard diet in accordance with the institutional 1 
guidelines of National Institutes of Health Guide for the Care and Use of Laboratory Animals.  2 
 3 
Renal function parameters. Mice were placed overnight in metabolic cages with ad libitum 4 
access to food and drinking water. Urines were collected over ice and body weight, water 5 
intake and diuresis were measured at the indicated time point (49). Blood (from sublingual 6 
vein) was obtained after anesthesia with ketamine/xylazine or isoflurane. Urine and blood 7 
parameters were measured using a UniCel DxC 800 pro Synchron (Beckman Coulter, 8 
Fullerton, CA, USA), whereas urinary Clara cell protein (CC16) concentration was measured 9 
in duplicate by enzyme-linked immunosorbent assay (ELISA; BIOMATIK EKU03200) (44). 10 
Albuminuria was measured by Coomassie Blue staining by using ProtoBlue Safe (EC-722, 11 
national diagnostics) according to manufacturer instructions.   12 
 13 
Kidney isolation and primary cultures of proximal tubule cells. The kidneys were harvested 14 
from OcrlY/+ and OcrlY/- mice and Clcn5Y/+and Clcn5Y/- mice as previously described (44). 15 
Briefly, one half of the kidney was fixed in 4% PFA and processed for immunostaining while 16 
the other half was used for protein isolation or RT-qPCR analysis. The contralateral kidney 17 
was taken to generate primary cultures of mouse proximal tubule cells (mPTCs) according to 18 
a previously established protocol (14). Confluent monolayers of mPTCs, characterized by a 19 
high endocytic uptake capacity, were expanded from tubular segments after 6–7 days. 20 
 21 
Genotyping. Genomic DNA was isolated from ear biopsies from OcrlY/+; Inpp5b -/-; BAC-22 
INPP5B and OcrlY/-; Inpp5b -/-; BAC-INPP5B mice by using E.Z.N.A Forensic DNA Kit 23 
(OMEGA bio-tek) according to the manufacturer instruction. PCR was performed by using 24 
the following primers: Ocrl wild-type: the forward primer 5’-CCC TTT 25 
TCATCTGTTAGGAGAAATC-3’is located at the junction of intron 18 and the 5’end of exon 26 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy449/5261432 by U
niversity of Zurich user on 07 January 2019
22 
 
19. The reverse primer 5’- GCATGG TTAAACGCACTATGTGG-3’ is located in intron 19, 1 
which is deleted in the OcrlY/- line. Ocrl knock-out: the forward primer 2 
5’GCCCTTTGATTCTAATCCCTTTTC ATC-3’ is located in the intron positioned just 3 
before the exon 19. The reverse primer 5’-TCT GAGCCCAGAAAGCGAAG-3’ is located in 4 
the PGK promoter, which is part of the neo-cassette gene targeting vector. Inpp5b knock-out: 5 
the forward primer 5’-TAAAGTCTGAAA ATCCAAGGC-3’ is located in exon 25. The 6 
reverse primer 5’-CTCATTTCTCCTTGATTC CAAT-3’ is located in exon 34. BAC-7 
INPP5B: the forward primer 5’-CCACCCCACGATTGACTC-3’ is localized in exon 1. The 8 
reverse primer 5’-GGTGTCCCAGCCCTCAG-3’ is localized also in exon 1. PCR conditions 9 
were: 32 cycles of 94°C for 30 sec, 55°C for 30 sec and 72°C for 1min. 10 
 11 
Quantitative real-time PCR. Total RNA was extracted from mouse kidney tissues using 12 
Aurum Total RNA Fatty and Fibrous Tissue Kit according to manufacturer’s protocol (Bio-13 
Rad, Hercules, CA). DNAse I treatment was performed to eliminate genomic DNA 14 
contamination. Total RNA was extracted from primary cell cultures with RNAqueous kit 15 
(Applied Biosystems, Life Technologies). 1 μg of RNA was used to perform the reverse 16 
transcriptase reaction with iScript™ cDNA Synthesis Kit (Bio-Rad). Changes in target gene 17 
mRNA levels were determined by relative RT-qPCR with a CFX96™ Real-Time PCR 18 
Detection System (BioRad) by using iQ™ SYBR Green Supermix (Bio-Rad). RT-qPCR 19 
analyses were performed in duplicate. Specific primers were designed by using Primer3 20 
(Supplementary Table 1). PCR conditions were 95°C for 3 min followed by 40 cycles of 15 21 
sec at 95°C, 30 sec at 60°C. The PCR products were sequenced with the BigDye terminator 22 
kit (Perkin Elmer Applied Biosystems, Thermo Fischer Scientific). The efficiency of each set 23 
of primers was determined by dilution curves (Supplementary Table 1). The relative changes 24 
in targeted genes over Gapdh, Actb, Hprt1, Ppiase, 18S, 36B4 mRNAs were calculated using 25 
the 2−ΔΔCt formula (50).   26 
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Immunofluorescence and confocal microscopy. Mouse kidneys were fixed by perfusion with 1 
50–60 ml of 4% PFA in PBS before being snap-frozen in cryogenic Tissue-Tek OCT 2 
compound (Electron Microscopy Sciences, Hatfield, USA). The embedded tissues were 3 
sectioned at 5 µm and processed for immunofluorescent staining as previously described (44). 4 
The slides were acquired on Leica SP5 confocal laser scanning microscope (Center for 5 
Microscopy and Image Analysis, University of Zurich) equipped with a Leica APO 63x NA 6 
1.4 oil immersion objective at a definition of 1024 x 1024 pixels, adjusting the pinhole 7 
diameter to 1 Airy unit for each emission channel. Quantitative image analysis was performed 8 
by selecting random visual fields containing at least 3-5 proximal tubules (LTL-positive) each 9 
one and acquired with the same setting parameters. For quantification of -lactoglobulin and 10 
dextran internalization, the integrated density signal detected within each LTL-positive tubule 11 
was calculated. Internalization was then expressed as a ratio between the internal fluorescence 12 
and tubule area. Tubules at the border of the picture were excluded. ImageJ software was used 13 
for the analysis (17). 14 
The mPTCs were fixed in 4% PFA and processed for immunofluorescent staining as 15 
previously described (44).  Briefly, after incubation with blocking/permeabilization solution 16 
(0.1% Saponin ,0.5% BSA and 50mM NH4Cl in PBS), mPTCs were stained overnight with 17 
the appropriate primary antibodies and 45 minutes with the suitable fluorophore-conjugated 18 
Alexa secondary antibodies (Invitrogen) or with Alexa-488 Phalloidin (F-actin) or 10 minutes 19 
with wheat germ agglutinin (WGA) FITC Conjugate. Immunostained mPTCs were 20 
analyzed by a Leica SP5 confocal laser scanning microscope using the settings described 21 
above. The quantitative cell image analyses were performed by using ImageJ software and the 22 
open-source cell image analysis software CellProfilerTM  (51). More details regarding the 23 
quantifications are described in Supplementary Materials. 24 
 25 
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Endocytosis assays. Proximal tubules endocytic capacity of Ocrl and Clcn5 mice was 1 
examined by measuring β-lactoglobulin and dextran uptake. β-lactoglobulin was tagged with 2 
Cy5 using TM2 Ab labeling kit (Amersham) in accordance with the manufacturer’s 3 
instructions. 15 minutes after tail-vein injection of Cy5 β-lactoglobulin (1mg/kg B.W., L3908, 4 
Sigma) or 30 minutes after injection of 10 kDa Alexa 647-dextran (6 mg/kg B.W.; D22914, 5 
Thermo Fisher Scientific), mice were anesthetized and their kidneys were harvested and 6 
processed for confocal microscopy. The endocytic capacity of Ocrl and Clcn5 mPTCs was 7 
examined by measuring albumin and dextran uptake as described previously (44). Briefly 8 
mPTCs were incubated at 37°C with 100g/mL Alexa488-BSA (A13100, Thermo Fisher 9 
Scientific) or 250g/mL Alexa 647-dextran diluted in medium without FBS 10 
supplementation, for 15 and 30 min respectively. After washing, the cells were fixed in 4% 11 
PFA and processed for confocal microscopy  12 
  13 
PI(4,5)P2 and PI3P staining. mPTCs were grown on 35mm dishes and PI(4,5)P2 or PI3P 14 
staining were performed according to previously established protocols (25). Briefly, mPTCs 15 
were fixed for 15 min in 2% PFA and permeabilized for 5 min with 20µM digitonin in buffer 16 
A (20mM PIPES pH 6.8, 137mM NaCl, 2.7mM KCl) for PI(4,5)P2 or buffer A
1 (150 mM 17 
NaCl, 20 mM Hepes, pH 7.4, and 2 mM EDTA) for PI3P. Next, mPTCs were incubated  for 18 
45 minutes with buffer A containing 10% fetal bovine serum and anti-PI(4,5)P2 antibody or 19 
in buffer A1 supplemented with 5% goat serum and mCherry-2×FYVE  PI3P-binding domain 20 
(gift from J.Gallop, Gurdon Institute, University of Cambridge). Anti –RFP was used for 21 
amplifying m-cherry staining. Studies of colocalization with early endosomes or lysosomes 22 
were performed by 1h incubation at room temperature with anti-EEA1 or anti-LAMP1 23 
antibodies respectively. After washing and subsequent incubation with appropriate secondary 24 
antibodies, mPTCs were post-fixed for 5 min in 2% PFA and analyzed by confocal 25 
microscopy.  26 
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Lysosomal activity and degradation assays. The detection of lysosomal activity and 1 
degradative capacity in mPTCs was performed by using Bodipy-FL-PepstatinA (P12271, 2 
Thermo Fischer Scientific) and DQ-RED BSA (D12051, Thermo Fischer Scientific), 3 
respectively. Briefly, mPTCs were pulsed with 1μM Bodipy-FL-Pepstatin A or with 10μg/mL 4 
DQ-RED BSA in pre-warmed media at 37°C for 1h. After washing, cells were fixed, 5 
immunostained with anti-LAMP1 and suitable secondary antibody and subsequently analyzed 6 
by confocal microscopy (14, 26).  Lysosomal processing in Ocrl and Clcn5 mice was 7 
measured by confocal analysis of kidney proximal tubules after 120 minutes from tail-vein 8 
injection of Cy5 β-lactoglobulin.  9 
 10 
Western blotting. Proteins were extracted from mouse kidney tissues or primary cultured cells 11 
and lysed as previously described (44). Samples were normalized for protein or urinary 12 
creatinine levels before loading (20 μg/lane or 4μg/lane, respectively), diluted in Laemmli 13 
buffer and separated by SDS–PAGE in reducing conditions. Briefly, gels were blotted onto 14 
PVDF membranes, blocked in 5% non-fat milk and probed with appropriate primary and 15 
peroxidase-labeled secondary antibody. Protein bands were visualized by chemiluminescence 16 
(WBKLS0050, Millipore, Life technologies). Image intensity was measured by ImageJ.  17 
 18 
Plasma membrane isolation. mPTCs were lysed in a fractionation buffer (250mM sucrose, 19 
20mM HEPES, 10mM KCL, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA) containing protease 20 
and phosphatase inhibitors and passed through a 25G needle. Cell lysates were kept on ice for 21 
20 minutes and centrifuged at 720 g (5 minutes at 4°C). The resultant postnuclear 22 
supernatants were centrifuged at 10,000 g (5 minutes at 4°C) to eliminate mitochondria. The 23 
postmitochondria supernatant were centrifuged at 100,000 g (1h at 4°C) to separate cytosolic 24 
(supernatant) and membrane fractions (pellet). The membrane pellets were washed in 25 
fractionation buffer by centrifugation (100,000 g for 45min at 4°C) and suspended in lysis   26 
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buffer (10% glycerol and 0.1% SDS supplemented with protease and phosphatase inhibitors). 1 
The cytosolic and membrane fractions were analyzed by SDS-PAGE and western blotting. 2 
 3 
Behavioral tests. Open field large arena test, water maze cue navigation and  three chambers 4 
sociability test were performed on a cohort of  32 male mice aged 32 weeks (16 5 
OcrlY/+;Inpp5b -/-;BAC-INPP5B and 16 OcrlY/-; Inpp5b -/-;BAC-INPP5B)  in order to 6 
investigate motor coordination, vision and  spatial learning and the social attitude of the mice 7 
respectively. Behavior testing procedures will be described briefly here and in more detail in 8 
the Supplementary Materials. Open field large arena test. Each subject was released near the 9 
wall of the arena and observed for 10 min on two subsequent days. Movements were tracked 10 
using Noldus EthoVision. Water-maze cue navigation. Animals were trained for 2 days to 11 
reach the goal platform hidden under milky-water and marked by a salient cue. The 12 
localization of the platform in the pool changed for every trial. All subjects were trained on 13 
the same sequence of goal positions and released from the same start points (52). Three-14 
chambers sociability test. The test consisted of a 10-minutes trial where a test mouse was 15 
given the choice to spend time in the chamber with the novel object (the cylinder) plus the 16 
unfamiliar mouse (social stimulus) and the chamber containing only the empty cylinder. The 17 
time spent by the test mouse in the lateral chambers was noted. (53). 18 
 19 
IntelliCages experiments. Intellicages experiments were performed on a cohort of 28 male 20 
mice aged 24 weeks (13 OcrlY/+; Inpp5b -/-, BAC-INPP5B and 15 OcrlY/-; Inpp5b -/-; BAC-21 
INPP5B). More details regarding the description of IntelliCage apparatus and mice 22 
preparation for IntelliCage experiments are provided in the Supplementary Materials.  23 
Exploration and free adaptation. During the first 4-7 days in IntelliCage all doors were 24 
open providing free access to all 8 drinking bottles (free adaptation). Data of the first 24h of 25 
free adaptation were analyzed separately to monitor exploration and habituation of the mice in 26 
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the new environment (IntelliCage exploration). Nosepoke adaptation. During 3-7 days, all 1 
doors were closed but can be opened at any time with a nosepoke for 5s once per visit. 2 
Drinking session adaptation. During 3-7 days the mice were adapted to a fixed drinking 3 
schedule with doors opening in response to nose pokes only in the following time spots: 4 
04:00-05:00, 11:00-12:00, 16:00-17:00 and 23:00-00:00. (30). 5 
 6 
Epon embedding and retinal morphology. 36 weeks old mice were euthanized and perfused 7 
with PFA 4%. Eyes were enucleated and post-fixed in 4% PFA or 2.5% glutaraldehyde before 8 
being embedded in paraffin or epon plastic, respectively. For light microscopy, paraffin 9 
sections (including the lens, 5 µm) were stained with hematoxylin-eosin (HE), while plastic-10 
embedded semi-thin cross-sections (0.5 μm) were counterstained with toluidine blue as 11 
described previously (54, 55). Retinal morphology was analyzed by light microscopy (Zeiss, 12 
Axioplan, Jena, Germany).  13 
 14 
Muscle analyses.  Muscles analyses were performed on OcrlY/+vs. OcrlY/- male mice aged 24 15 
weeks. Lean mass/body weight ratio was determined in 6 pairs of live mice by using the 16 
whole body composition analyzer EchoMRI™ (Zinsser Analytic, Frankfurt, Germany) (56). 17 
Five pairs of mice were used for muscle and blood sampling. The mice were slightly sedated 18 
using isoflurane before being anesthetized with an i.p. injection of a mixture containing 19 
urethane (1.5 g/kg) and diazepam (5 mg/kg) and killed by exsanguination. Blood and muscle 20 
tissues were collected as previously described (57). Selected leg muscles (triceps surae, 21 
soleus, plantaris, gastrocnemius, tibialis anterior, tibialis posterior, quadriceps) were carefully 22 
dissected bilaterally and weighed. Muscle mass was expressed relative to body weight. 23 
Creatine kinase (CK) activity in plasma was determined by spectrophotometry using a kit 24 
(C184-0B ; Catachem, Nuuchem, Oxford, CT, USA) according to the manufacturer’s 25 
instructions (57). 26 
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Data analysis and Statistics. The quantitative data were expressed as means ± standard error 1 
of the mean (s.e.m.). Differences between experimental groups were evaluated using analysis 2 
of variance followed by post hoc test, when appropriate. When only two groups were 3 
compared, unpaired or paired two tailed Student’s t-tests were used as appropriate. No 4 
statistical methods were used to predetermine the sample size. The sample size (n of 5 
biological replicates derived from distinct mice) of each experimental group is described in 6 
figure legends. GraphPad Prism software was used for all statistical analyses. Statistical 7 
significance was set at a P<0.05. 8 
  9 
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FIGURE LEGENDS 1 
Figure 1. Growth retardation and renal phenotype in a whole body OcrlY/- mouse model. 2 
(A) Dot plot representing the measurement of body weight, (B) albumin and (D) clara cell 3 
protein 16 (CC16) urinary excretion in Ocrl male mice at 8, 16, 24 and 48 weeks after birth (8 4 
weeks n= 7 mice per group, 16 weeks n= 7 mice per group, 24 weeks n=7 mice per group, 48 5 
weeks n=5 mice per group). (C) Coomassie blue-stained SDS-PAGE analysis of urine derived 6 
from 8 weeks old Ocrl mice and densitometry quantification of Albumin (n=3 mice per 7 
group).10 μg of bovine serum albumin (BSA) were loaded as positive control (first lane; 8 
molecular weight (MW) 66.5 kDa). (E) Representative western blotting and densitometry 9 
quantification of transferrin (TFR), vitamin D binding protein (VDBP) and CC16 in urine 10 
derived from 8 weeks old Ocrl mice. (TFR, VDBP and CC16 n= 5 mice per group). (F) 11 
Quantification of CC16 urinary excretion in 8 weeks old Clcn5 and Ocrl mice (n=5 mice per 12 
group). All the urine parameters were normalized to urinary creatinine concentration. Plotted 13 
data represent mean ± SEM. Each dot of the graphs represents one mouse. Two-tailed 14 
unpaired Student’s t-test, *P < 0.05, **P < 0.01 and ***P < 0.001 relative to OcrlY/+ or 15 
Clcn5Y/+ mice. ns: not significant. 16 
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Figure 2. Defective receptor-mediated endocytosis in OcrlY/- mice.  1 
(A-B) Representative confocal micrographs showing Cy5 labeled β-lactoglobulin (red, 2 
1mg/kg B.W.) or (C) Alexa 647–labeled dextran uptake (red, 6 mg/kg B.W.) after 15 and 30 3 
minutes from tail vein injections respectively and quantifications of the corresponding 4 
fluorescent signal in LTL+ (Lotus Tetragonolobus Lectin, green) proximal tubules from Ocrl 5 
and Clcn5 mouse kidneys (n=90 Ocrl and n=70 Clcn5 proximal tubules for Cy5 labeled β-6 
lactoglobulin uptake;  n = 40 Ocrl proximal tubules for Alexa 647 dextran uptake); n=2 per 7 
group, each dot representing fluorescence intensity in one proximal tubule; fluorescence 8 
intensity was normalized on tubule area; two-tailed unpaired Student’s t-test, ***P < 0.001 9 
relative to OcrlY/+or Clcn5Y/+ kidneys. ns: not significant). Insets: high magnification of Cy5 10 
labeled β-lactoglobulin+ or Alexa 647 dextran+ structures in LTL+ proximal tubules. (D) 11 
Representative confocal micrographs showing LRP2 (red) expression in LTL+ (green) 12 
proximal tubules of Ocrl mouse kidneys. Insets: high magnification of LRP2+ structures in 13 
LTL+ proximal tubules. (E) Western blotting and densitometry analyses of LRP2, SGLT2, 14 
NaPi-IIa and AQP1 protein levels in whole kidney lysates from Ocrl mice. β-actin was used 15 
as loading control. Protein levels normalized on β-actin and relative to OcrlY/+ mice (black 16 
dotted line), (LRP2 n = 6 mice per group; SGLT2, NaPiIIa and AQP1 n=3 mice per group. 17 
Mann-Whitney U test, **P < 0.01 relative to OcrlY/+ kidneys). (F) The mRNA kidney levels 18 
of Lrp2, Sglt2, Slc34a1 and Aqp1 were analyzed by real-time qPCR. Gene target expression 19 
normalized to Gapdh and relative to OcrlY/+ mice (black dotted line), (n = 3 mice per group). 20 
Nuclei counterstained with DAPI (blue) in A, B, C and D. Scale bars 25µm. Plotted data 21 
represent mean ± SEM.  22 
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Figure 3. Altered PI(4, 5) P2  subcellular distribution and receptor-mediated endocytosis 1 
in OcrlY/- mPTCs.  2 
(A) Representative confocal micrographs and quantification of PI(4,5)P2
+ structures (green) in 3 
Ocrl mPTCs (n  80 cells pooled from three mouse kidneys per condition; each dot 4 
representing the number of PI(4,5) P2
+ structures in a cell). (B) Representative confocal 5 
micrographs of Ocrl mPTCs immunostained with anti- PI(4,5)P2 (green) and anti-EEA1 (red, 6 
early endosomes) and quantification (adjacent panel) of the number of PI(4,5)P2/EEA1
+ 7 
structures by confocal microscopy (percentage of total EEA1+ vesicles; n= 3 OcrlY/+; n=4 8 
OcrlY/-  randomly selected fields per condition, each containing  15-20 cells). Insets: high 9 
magnification of PI(4,5)P2/EEA1
+ structures. (C-D) Ocrl and Clcn5 mPTCs were loaded with 10 
Alexa 488-BSA (green, 100 μg ml−1 for 15 min at 37 °C), fixed, and analyzed by confocal 11 
microscopy. Quantification of the number of Alexa 488-BSA+ structures (n 150-250 cells 12 
pooled from three mouse kidneys per condition; each point representing the number of BSA+ 13 
structures in a cell). (E) Ocrl mPTCs were loaded with Alexa 647-dextran 10kDa (red, 250 μg 14 
ml−1 for 30 min at 37 °C), fixed, and analyzed by confocal microscopy. Quantification of the 15 
number of Al647-dextran+ structures (n 200-250 cells pooled from three mouse kidneys per 16 
condition; each dot representing the number of dextran+ structures in a cell). Nuclei 17 
counterstained with DAPI (blue). Scale bars in A and B 15μm, in C, D and E 10 μm. Plotted 18 
data represent mean ± SEM. Two-tailed unpaired Student’s t-test, **P < 0.01, ***P < 0.001 19 
relative to OcrlY/+ or Clcn5Y/+ mPTCs. ns: not significant.  20 
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Figure 4. OcrlY/- mPTCs exhibit decreased expression of LRP2 and defective endocytic 1 
recycling.  2 
(A) Representative western blotting and quantification of LRP2 in whole Ocrl mPTCs lysates. 3 
α- tubulin was used as loading control (n=4 mice per group). (B) Dot plot representing 4 
distribution and average fluorescence intensity of LRP2 along Z-stacks projections in Ocrl 5 
mPTCs. Yellow rhombus represents the maximum peak of fluorescence intensity. 6 
Quantifications of Z-stacks were obtained from 3 randomly selected fields per condition, with 7 
each containing  15-20 cells. (C) Representative confocal micrographs and quantification of 8 
LRP2/WGA+ structures by confocal microscopy (in percentage of total LRP2+ vesicles, n=7 9 
OcrlY/+; n=8 OcrlY/- randomly selected fields per condition, each containing 10-15 cells). (D) 10 
Representative western blotting and quantification of LRP2 protein levels in plasma 11 
membrane fraction derived from Ocrl mPTCs. Flotillin A1 and GAPDH were used as purity 12 
marker and loading control of the plasma membrane and cytosolic fractions respectively (n=3 13 
independent experiment). (E) Representative confocal micrographs of Ocrl mPTCs 14 
immunostained with anti-LRP2 (red) and anti-EEA1 (green, early endosomes) and 15 
quantification (adjacent panel) of the number of LRP2/EEA1+ structures by confocal 16 
microscopy (percentage of total LRP2+ vesicles; n=5 OcrlY/+; n=6 OcrlY/- randomly selected 17 
fields per condition, each containing  15-20 cells). Insets: high magnification of 18 
LRP2/EEA1+ structures. (F) Representative confocal micrographs of Ocrl mPTCs 19 
immunostained with anti-LRP2 (red) and Alexa-Fluor-488-phalloidin (green, F-actin). 20 
Quantification (adjacent panel) of the number of F-Actin/LRP2+ structures (in percentage of 21 
total LRP2+ vesicles, n= 4 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, each 22 
containing 10-15 cells). Insets: high magnification of F-actin/LRP2+ structures. (G) 23 
Representative confocal micrographs of Ocrl mPTCs stained with anti-TfR (green) and anti-24 
LRP2 (red) and quantification of the number of TfR/LRP2+ structures by confocal 25 
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microscopy (in percentage of total LRP2+ vesicles, n=8 randomly selected fields per 1 
condition, each containing 20-25 cells). Insets: high magnification of TfR/LRP2+ structures. 2 
Nuclei counterstained with DAPI (blue) in C, E, F and G. Scale bars in E, F and G 15μm and 3 
in C 20μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, *P < 4 
0.05, **P < 0.01 and ***P < 0.001 relative to OcrlY/+ mPTCs.  5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy449/5261432 by U
niversity of Zurich user on 07 January 2019
45 
 
Figure 5.  Altered lysosomal dynamics and degradative capacity in OcrlY/- mPTCs.  1 
(A) Ocrl mPTCs were immunostained with anti-PI(4,5)P2 (green) and anti-LAMP1 (red, 2 
lysosomes) and the number of PI(4,5)P2 /LAMP1
+ structures were quantified by confocal 3 
microscopy (in percentage of total PI(4,5)P2
+ vesicles; n=3  randomly selected fields per 4 
condition, each containing  40-50 cells). (B) Representative confocal micrographs of Ocrl 5 
mPTCs immunostained with anti-LAMP1 (green). Quantification of the average LAMP1+ 6 
vesicles diameter (top, n= 4 OcrlY/+ ; and n=6 OcrlY/- randomly selected fields per condition, 7 
each containing  50-60 cells) and number of structures (bottom, n 200-220 cells pooled 8 
from 3 Ocrl kidneys per group, each point representing the number of LAMP1+ structure in a 9 
cell ). (C) Ocrl mPTCs were loaded with DQ (dequenched) Red BSA (red, 10 μg ml−1 for 1h 10 
at 37 °C), immunostained with anti- LAMP1 (green, lysosomes) fixed and analyzed by 11 
confocal microscopy. Quantification of number of DQ Red BSA /LAMP1+ structures (in 12 
percentage of total LAMP1+ structures, n = 8 randomly selected fields per condition, with 13 
each containing  10–15 cells). Insets: high magnification of DQ Red BSA / LAMP1+ 14 
vesicles. (D) Ocrl mPTCs were serum starved for 24 h and then stimulated with EGF (100 15 
ng/ml) for the indicated times. EGFR protein levels were evaluated by western blotting and 16 
quantified relative to time 0 (starved cells). (n=3mice per group; two-tailed unpaired 17 
Student’s t-test, *P < 0.05, **P < 0.01 relative to OcrlY/+ or OcrlY/- starved mPTCs. ns: not 18 
significant). (E) Western blotting and densitometry analyses of Cathepsin D (Cts-D) protein 19 
levels in Ocrl mPTCs (n= 4mice per group). (F) Ocrl mPTCs were loaded with Bodipy-FL-20 
PepA (1 μM, for 1 h at 37 °C, green), immunostained with anti- LAMP1 antibody (red) and 21 
analysed by confocal microscopy. Quantification of numbers of PepA/LAMP1+ structures (in 22 
percentage of total LAMP1+ structures; n = 4 randomly selected fields per condition, with 23 
each containing ~ 20–25 cells). (G) Representative confocal micrographs showing Cy5 24 
labeled β-lactoglobulin (red) after 120 minutes from tail vein injections and quantifications of 25 
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the corresponding fluorescent signal in LTL+ proximal tubules from Ocrl mouse kidneys 1 
(n=50 Ocrl proximal tubules; each dot representing fluorescence intensity in one proximal 2 
tubule; fluorescence intensity was normalized on tubule area). Nuclei counterstained with 3 
DAPI (blue) in A, B, C, F and G. Scale bars in A, B and C 15 μm; in F 10 μm and in G 50 4 
μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test.  **P < 0.01, 5 
***P < 0.001 relative to OcrlY/+ mPTCs or kidneys.   6 
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Figure 6. Impaired locomotor activity and muscular defects in OcrlY/- mice.  1 
(A-C) Open field large arena test was performed during 10 minutes of two subsequent days in 2 
a circular arena with a diameter of 150 cm on a cohort of 16 OcrlY/+and 16 OcrlY/- age 3 
matched male mice. (A) Illustrative pictures representing the trajectories traveled by Ocrl 4 
mice during the open field large arena test. (B) Dot plot representing the distance covered by 5 
Ocrl mice during the large open field arena test. The distance traveled by each mouse is 6 
normalized to 1 minute observation time and plotted as function of time for each bin (bin=5 7 
minutes) (split ANOVA effects followed by post-hoc tests between genotype for each bin: 8 
Bin1 ’P < 0.1, Bin2 *P < 0.05, Bin3 *P < 0.05). (C) Dotted bar graph representing the 9 
frequency of resting, lingering and walking episodes exhibited by Ocrl mice during the open 10 
field large arena test (split ANOVA effects followed by post-hoc tests between genotype for 11 
each state: rest *P < 0.05, linger, *P < 0.05, walk *P < 0.05). (D) IntelliCage experiments 12 
were performed on a cohort of age matched male Ocrl mice (13 OcrlY/+and 13 OcrlY/-). Dot 13 
plot representing the median licking frequency during drinking restriction protocol. Base 14 
indicates the licking frequency during the last 24h of nose poke adaptation phase (split 15 
ANOVA effects followed by post-hoc tests between genotype for each time point: Day1 **P 16 
< 0.01, Day 2-2last *P < 0.05, Last day **P < 0.001). (E) Lean mass/body weight ratio 17 
determined by whole body composition analysis in Ocrl mice (n=6 mice per group). (F) 18 
Muscle mass, relative to body weight, of selected hind limb muscles obtained by bilateral 19 
dissection of 5 pairs of Ocrl mice (n=10 values for symmetrical leg muscles). (G) Plasma 20 
creatine kinase activity (CK) in the corresponding 5 pairs of Ocrl mice (as in B). Plotted data 21 
represent mean ± SEM. In B, C and D One-way ANOVA between subject factor genotype: 22 
*P < 0.05; **P < 0.01 (on the top of each graph); in E, F and G Mann Withney test, **P < 23 
0.01; ***P < 0.001 relative to OcrlY/+ mice. 24 
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Table 1. Body weight, urine and blood parameters in Ocrl and Clcn5 mice. 
 
U, Urine; CC16, Clara cell protein 16; BUN, Blood urea nitrogen. All the measurements were performed on OcrlY/+ and OcrlY/- male mice matched per age. 
Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test was applied between genotypes for the indicated time point. 
a
p< 0.05 versus Ocrl 
Y/+ 
or Clcn5
Y/+
 ; 
b
p< 0.01 versus Ocrl 
Y/+
or Clcn5
Y/+; cp< 0.001 versus Ocrl 
Y/+ or Clcn5
Y/+
. 
 
 
8 weeks 8 weeks 16 weeks 24 weeks 48 weeks 
Ocrl
Y/+
 (n= 7) Ocrl
Y/- 
 (n= 7) Clcn5
Y/+
(n=4) Clcn5
Y/-
(n=4) Ocrl
Y/+
 (n= 7 ) Ocrl
Y/- 
 (n= 7) Ocrl
Y/+
 (n= 7 ) Ocrl
Y/- 
 (n= 7) Ocrl
Y/+
 (n= 5 ) Ocrl
Y/- 
 (n= 5) 
Body weight 
(gr.) 
24.6 ± 0.8 25.8 ± 0.4 31.03 ± 1.3 27.2 ±  1.2 31.3 ± 0.9 26.6 ± 0.9a 36.3 ± 0.9 32.2 ± 0.7a 40.1 ± 2.5 33.1 ± 1.8b 
U volume 
(µL/12h) 
2267 ± 337 3122 ± 328 1400 ± 82 3025 ± 111c 2414 ± 298 3571 ± 561 2388 ± 650 2462 ± 544 1655 ± 315 2138 ± 555 
Diuresis 
(μL/gr. B.W./min) 
0.12 ± 0.02 0.16 ± 0.01 0.06 ± 0.004 0.15 ± 0.004b 0.1 ± 0.01 0.18 ± 0.03 0.09 ± 0.02 0.11 ± 0.02 0.06 ±0.01 0.091 ± 0.02 
U Albumin 
(mg/gr creatinine) 
0.97 ± 0.3 21 ± 1.1c 3.3 ± 0.2 69 ± 13b 9.2 ± 2.3 27.9 ± 3.1c 11.8 ± 3.4 25.7 ± 2.1c 8.6 ± 2.5 39.5 ± 3.2c 
U CC16 
(mg/gr creatinine) 
0.14 ± 0.02 1.9 ± 0.2c 0.09 ± 0.02 19.2 ± 1.9c 0.03 ± 0.00 2.5 ± 0.3c 0.05 ± 0.01 2.9 ± 0.3c 0.06 ± 0.02 2.9 ± 0.2c 
U Calcium 
(mg/gr.creatinine) 
94.9 ± 6.4 73.9 ± 14.5 58.2 ± 16.4 144 ± 11.6b 135 ± 11.2 148 ± 14.3 70.4 ± 20.3 93.8 ± 8 148 ± 23 109 ± 11.5 
U Glucose 
(mg/gr. creatinine) 
1561 ± 136 1451 ± 95 1122 ± 76 1982 ± 341a 1440 ± 171 1418 ± 163 1081 ± 179 1672.7 ± 493 3040 ± 993 1534 ± 93 
U Phosphate 
(mg./gr. creatinine) 
4051 ± 419 4316 ± 160 2684 ± 314 4294 ± 448a 4436 ± 403 4017 ± 372 2584 ± 422 2761 ± 423 3072. ± 434 3101 ± 106 
U Creatinine 
(mg/dL) 
26 ± 1.8 24 ± 1.5 31 ± 1.9 30 ± 2.5 23.4 ± 2.8 19.5 ± 1.9 35.5 ± 6.4 29.9 ± 3.8 25.4± 5 27.5 ± 1.9 
BUN 
(mg/dL) 
    22 ± 1.5 22 ± 1.3   23.8 ± 2.7 22.3 ± 1.2 
Plasma Creatinine 
(mg/dL) 
    0.09 ± 0.02 0.08 ± 0.006   0.05 ± 0.007 0.06 ± 0.01 
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ABBREVIATIONS 
OCRL: Lowe Oculocerebrorenal syndrome  
INPP5B: Inositol Polyphosphate-5-Phosphatase B 
PI(4,5)P2: phosphatidylinositol 4, 5-bisphosphate  
PI3P: phosphatidylinositol 3-phosphate 
PT: proximal tubule 
mPTCs: mouse primary culture of proximal tubule cells 
LMW: low-molecular-weight  
CKD: chronic kidney disease 
PH: pleckstrin homology 
ASH: ASPM, SPD-2, Hydin domain 
BAC: bacterial artificial chromosome  
TFR: transferrin  
VDBP: vitamin D binding protein  
CC16: Clara Cell Secretory protein 16 
ClC-5: chloride-proton exchanger 5 
NaPi-IIa: sodium- phosphate cotransporter IIa  
SGLT2: sodium-glucose cotransporter 2 
BSA-DQ: dequenched BSA 
EGFR: epidermal growth factor receptor  
Cts-D: Cathepsin D 
PepA: PepstatinA  
rd8: retinal degeneration 8 
V-ATPase: vacuolar-type H+-ATPase  
CI-MPR: cation-independent mannose 6-phosphate receptor  
CTNS: cystinosin 
CK: creatine kinase 
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